Incidence of β-Lactam–Induced Delayed Hypersensitivity and Neutropenia During Treatment of Infective Endocarditis

Olaison, Lars; Belin, Lars; Hogevik, Harriet; Alestig, Kjell

doi:10.1001/archinte.159.6.607

Cited by 73 publications

(79 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antistaphylococcal penicillins are well known for inducing allergic interstitial nephritis characterized by acute and often severe renal failure, as well as dose-dependent hypersensitivity hepatitis (24)(25)(26), which can correspond to the acute renal failure cases (n ϭ 4) and hepatobiliary disorders (n ϭ 2) observed in our series. Hematologic reactions (n ϭ 7) are also frequently immune-mediated and can consist of neutropenia, hemolytic anemia, or acute thrombopenia (25,27).…”

Section: Resultsmentioning

confidence: 99%

Antimicrobial-Related Severe Adverse Events during Treatment of Bone and Joint Infection Due to Methicillin-Susceptible Staphylococcus aureus

Valour

Karsenty

Bouaziz

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Bone and joint infections (BJI), including septic arthritis, osteomyelitis, and orthopedic device-related infections (ODI), constitute difficult-to-treat clinical entities, as they chronically evolve and frequently cause a relapse in infection (1-4). Staphylococcus aureus is the leading cause of BJI, accounting for approximately 50% of cases, and it is particularly associated with treatment failure due to its various virulence factors, including its great ability to form biofilms (5-7). These concerns have led to the recommendation of a prolonged antimicrobial course in S. aureus BJI, frequently in combination to avoid the acquisition of drug resistance, with initial administration via the intravenous route and at a high dosage (8-10). It is well known that the prolonged use of antimicrobial combinations is associated with an increased toxicity risk (11), but only limited and conflicting data are found in the literature concerning the prevalence and predictive factors of antimicrobial-related adverse events (AE) occurring during the treatment of BJI. A recent meta-analysis concluded that the incidences of AE are 16.1% for mild AE and 7.7% for moderate and severe AE (12), but some studies found the incidence of AE can reach rates as high as 50% of the patients (13,14). We aimed to describe the occurrence of and risk factors for antimicrobial-related AE in a retrospective cohort study that included patients admitted to a regional reference center with methicillin-susceptible S. aureus (MSSA) BJI. MATERIALS AND METHODSEthics statements. This study received the approval of the French SouthEast ethics committee with the reference number CAL2011-021. In accordance with French legislation, written informed patient consent was not required for any part of the study.Inclusion criteria and data collection. All patients with MSSA BJI who followed up in our institution between 2001 and 2011 were enrolled in a retrospective cohort study. Patients with diabetic foot-and decubitus ulcer-related BJI were excluded because of the particular pathophysiology proceeded by contiguity with bone exposition and implicating diabetesassociated vascular disease and peripheral neuropathy, leading to a specific management of these infections. For each patient, data were collected from medical records, nursing charts, and biological software in an anonymous standardized case report form.Definitions. BJI diagnosis was based upon the existence of clinical and biological evidences of infection and at least one reliable bacteriological

show abstract

Section: Resultsmentioning

confidence: 99%

Antimicrobial-Related Severe Adverse Events during Treatment of Bone and Joint Infection Due to Methicillin-Susceptible Staphylococcus aureus

Valour

Karsenty

Bouaziz

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…b-Lactam antibiotics, in general [7][8][9][10][11], and piperacillin [9] and piperacillin-tazobactam, in particular [10], can lead to reversible neutropenia in patients receiving treatments lasting 110 days [11]. Although the incidence of neutropenia induced by treatment with b-lactam antibiotics has been studied in relation to such infections as endocarditis [8,12], cystic fibrosis [13], and osteomyelitis [9], little information is available on the side effects of prolonged therapy with piperacillin-tazobactam in patients with bone-related infections. The present study assesses the incidence of piperacillintazobactam-related neutropenia among patients receiving prolonged treatments for bone-related infections.…”

mentioning

confidence: 99%

Incidence of Neutropenia during Treatment of Bone-Related Infections with Piperacillin-Tazobactam

Peralta

Sánchez

Roiz

et al. 2003

Clinical Infectious Diseases

View full text Add to dashboard Cite

Of 41 patients with bone-related infections who were treated for > or =10 days with piperacillin-tazobactam, 14 (34%) developed neutropenia. Cumulative doses of piperacillin administered to neutropenic patients were higher than those administered to nonneutropenic ones (330 vs. 237 g; P=.008), and an inverse correlation was detected between the absolute neutrophil count at the end of treatment and the cumulative dose of piperacillin (r=-0.47, P=.002). Moreover, the incidence of piperacillin-tazobactam-induced neutropenia increased with an increase in the cumulative dose of piperacillin: 0% of patients in the first quartile of cumulative piperacillin doses, 33.3% in the second quartile, 40% in the third quartile, and 66.7% in the fourth quartile.

show abstract

“…Another suggested mechanism is direct toxicity to the bone marrow. This has been supported by hypo-cellular marrow with maturation arrest on bone marrow biopsy [7].…”

Section: Introductionmentioning

confidence: 83%

Vancomycin-associated neutropenia in hemodialysis patient with sepsis

Altawil¹,

Aljamaan²

2017

IJCRI

View full text Add to dashboard Cite

Incidence of β-Lactam–Induced Delayed Hypersensitivity and Neutropenia During Treatment of Infective Endocarditis

Abstract: Background: Long-term parenteral ␤-lactam treatment is often complicated by adverse reactions that necessitate drug withdrawal.

Cited by 73 publications

References 53 publications

Antimicrobial-Related Severe Adverse Events during Treatment of Bone and Joint Infection Due to Methicillin-Susceptible Staphylococcus aureus

Antimicrobial-Related Severe Adverse Events during Treatment of Bone and Joint Infection Due to Methicillin-Susceptible Staphylococcus aureus

Incidence of Neutropenia during Treatment of Bone-Related Infections with Piperacillin-Tazobactam

Vancomycin-associated neutropenia in hemodialysis patient with sepsis

Contact Info

Product

Resources

About